Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q1 2026 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Taysha Gene Therapies First Quarter 2026 Financial Results Conference Call.
Taysha Gene Therapies Inc. (TSHA)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Leucadia National Ian Cumming And Joseph Steinberg | 479,000 | $2,141,130 | +1816% | 0.01% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.75 | 750,000 | $2,062,500.00 | 2,841,704 | 2025-05-30 | Filing | |
| $2.25 | 1,333,333 | $2,999,999.25 | 1,333,333 | 2024-06-27 | Filing | |
| $1.63 | 100,000 | $163,000.00 | 16,566,667 | 2023-11-17 | Filing | |
| $0.90 | 16,466,667 | $14,820,000.30 | 16,466,667 | 2023-08-16 | Filing | |
| $0.90 | 388,889 | $350,000.10 | 999,381 | 2023-08-16 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $4.46 | 200,000 | $892,000.00 | 1,136,410 | 2026-04-10 | Filing | |
| $4.52 | 1,655 | $7,480.60 | 1,442,131 | 2026-02-04 | Filing | |
| $4.61 | 26,918 | $124,091.98 | 1,317,389 | 2026-01-26 | Filing | |
| $4.75 | 89,132 | $423,377.00 | 1,344,307 | 2026-01-23 | Filing | |
| $4.61 | 41,312 | $190,448.32 | 2,908,257 | 2026-01-26 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 10,231,502 | $45,734,814 | 0% | |
| 2. | 2,022,498 | $9,040,566 | 0% | |
| 3. | 1,530,461 | $6,841,161 | 0% | |
| 4. | 1,021,063 | $4,564,152 | 0.01% | |
| 5. | 849,212 | $3,795,977 | 1.17% |
News See All
10 Best Small-Cap Biotech Stocks to Buy According to Hedge Funds
On February 16, Franklin Equity said the biotechnology industry has entered 2026 on a firmer footing following an extended period of market uncertainty in the prior year, noting that market attention ...
9 Best Healthcare Penny Stocks to Buy According to Hedge Funds
Volatility in the equity market has been on another level in the first quarter of the year.
10 Best Multibagger Penny Stocks to Invest In
Small-cap and penny stocks are often overlooked by Wall Street as they tend to be extremely volatile.
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q4 2025 Earnings Call Transcript
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q4 2025 Earnings Call Transcript March 19, 2026Taysha Gene Therapies, Inc. beats earnings expectations.
Taysha Gene Therapies, Inc. (TSHA) Gains Wells Fargo's Support on Rett Syndrome Program Progress
TheFly reported on January 5 that Wells Fargo raised its price target on TSHA to $11 from $8 and maintained an Overweight rating.
20 Best Biotech Stocks Under $20 to Buy Now
The U.S. biotechnology market enters 2026 as the largest global biotech market, with an estimated size of $552.39 billion in 2023, and is projected to grow to $1.24 trillion by 2030.
Here's What Analysts Are Saying About Taysha Gene Therapies (TSHA)
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) is one of the best strong buy stocks to invest in under $5. Needham maintained a bullish outlook on Taysha Gene Therapies, Inc.
10 Best Strong Buy Stocks to Invest In Under $5
On January 28, JoAnne Feeney, Advisors Capital Management partner and portfolio manager, appeared on CNBC’s ‘Squawk Box’ to talk about the latest market trends. She was of the view that there is...
Taysha Gene Therapies Inc. (TSHA): A Promising Biotech on Rett Syndrome Drug Prospects
Taysha Gene Therapies Inc. (NASDAQ:TSHA) is one of the best penny stocks to buy for 2026. On January 6, the company confirmed that the dosing of the first patient in the REVELA pivotal trial began.
Hedge Fund Resource Center